Migraine is a neurological disease that is defined by recurrent attacks of disabling headaches. Its headache episodes can potentially have a disabling impact on the different functioning of the subjects. Erenumab is one of four monoclonal antibodies that have been developed as migraine preventive therapy. However, erenumab is the only, fully humanized one with the most known efficient vasodilator peptide approved for use in migraine. This study was conducted to assess erenumab efficacy and safety for the preventive treatment of migraine by reviewing the previous research reported on this subject. Previous research was obtained by searching the scientific databases using relevant terms. Eligible studies were limited to original English articles that were available in full text with an analysis of original data. Eight studies of 2,269 patients were enrolled; the population involved subjects with episodic, chronic, and resistant chronic migraine. Erenumab doses were injections of 70 and 140 mg per month. The major findings, included erenumab effectiveness, adverse effects, and efficacy associated variables. Erenumab of either available dose was effective and safe as migraine preventive treatment with few non-significant adverse effects and no gender differences regarding effectiveness and adverse effects.
Key words: Erenumab, safety, efficacy, migraine, systemic review
|
